QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal

Sunday, August 14, 2016 General News J E 4
Proposal would adjust capital structure through 4% reduction in number of shares outstanding and direct capital repayment to shareholders

VENLO, Netherlands, August 14, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to return approximately $250 million to shareholders through a synthetic share repurchase proposal that combines a direct capital repayment with a reverse stock split.

These actions, which will lead to an adjustment in QIAGEN's share capital, have been used previously by other large, multinational Dutch companies as an efficient way to provide returns to shareholders. The proposal, if adopted, is expected to be similar to QIAGEN repurchasing approximately $250 million of its own shares, but will enable the return of capital to all shareholders in a much faster and more efficient way than through a traditional open-market repurchase program.

QIAGEN intends to fund the capital repayment, which forms part of a commitment announced in July 2016 to return $300 million to shareholders by the end of 2017, from existing cash reserves and expects to maintain its current non-rated, investment-grade credit profile. The adjustment to QIAGEN's capital structure will be proposed at an Extraordinary General Meeting of Shareholders (EGM), which is scheduled to take place in October 2016. The related series of transactions are expected to be completed in early January 2017, in part due to a Dutch legal requirement for a two-month creditor objection period after shareholder approval of the proposal. No Dutch dividend withholding tax is expected to be applicable.

Click here for full press release{48B284C1-4F8C-457E-ACB3-D5BA9489BB14}&lang=en


Contact: Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49 2103 29 11826 Email: Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 11711 Email:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Microscopy Market to see 7.5% CAGR led by Electron...
Assisi Animal Health Shares Four Nutrition Tips fo...